Laboratory Medicine ›› 2021, Vol. 36 ›› Issue (6): 609-614.DOI: 10.3969/j.issn.1673-8640.2021.06.007
Previous Articles Next Articles
LI Jing, QUAN Hui(), ZENG Zhirong, WEI Yi
Received:
2020-06-29
Online:
2021-06-30
Published:
2021-06-30
Contact:
QUAN Hui
CLC Number:
LI Jing, QUAN Hui, ZENG Zhirong, WEI Yi. Establishment of the reference interval of small and dense low-density lipoprotein cholesterol in apparently healthy adults in Chengdu[J]. Laboratory Medicine, 2021, 36(6): 609-614.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2021.06.007
性别 | 例数 | TC/(mmol/L) | TG/(mmol/L) | HDL-C/(mmol/L) |
---|---|---|---|---|
男性 | 474 | 4.31±0.57 | 1.02(0.79~1.27) | 1.31±0.21 |
女性 | 372 | 4.23±0.57* | 0.84(0.65~1.10)* | 1.48±0.26* |
合计 | 846 | 4.28±0.57 | 0.93(0.73~1.22) | 1.39±0.25 |
性别 | LDL-C/(mmol/L) | apo A1/(g/L) | apo B/(g/L) | sd-LDL-C/(mmol/L) |
男性 | 2.18±0.46 | 1.37±0.20 | 0.78±0.15 | 0.59(0.46~0.77) |
女性 | 1.97±0.46* | 1.50±0.26* | 0.70±0.15* | 0.48(0.38~0.61)* |
合计 | 2.09±0.47 | 1.42±0.24 | 0.74±0.16 | 0.53(0.42~0.77) |
性别 | 例数 | TC/(mmol/L) | TG/(mmol/L) | HDL-C/(mmol/L) |
---|---|---|---|---|
男性 | 474 | 4.31±0.57 | 1.02(0.79~1.27) | 1.31±0.21 |
女性 | 372 | 4.23±0.57* | 0.84(0.65~1.10)* | 1.48±0.26* |
合计 | 846 | 4.28±0.57 | 0.93(0.73~1.22) | 1.39±0.25 |
性别 | LDL-C/(mmol/L) | apo A1/(g/L) | apo B/(g/L) | sd-LDL-C/(mmol/L) |
男性 | 2.18±0.46 | 1.37±0.20 | 0.78±0.15 | 0.59(0.46~0.77) |
女性 | 1.97±0.46* | 1.50±0.26* | 0.70±0.15* | 0.48(0.38~0.61)* |
合计 | 2.09±0.47 | 1.42±0.24 | 0.74±0.16 | 0.53(0.42~0.77) |
组别 | 例数 | TC/(mmol/L) | TG/(mmol/L) | HDL-C/(mmol/L) |
---|---|---|---|---|
男性 | ||||
20~29岁组 | 94 | 4.15(2.80~4.90) | 0.85(0.43~1.41)* | 1.29(1.00~1.56)* |
30~39岁组 | 99 | 4.38(3.29~5.08)* | 1.05(0.61~1.53)* | 1.31(1.01~1.59)* |
40~49岁组 | 123 | 4.43(2.95~5.10) | 1.04(0.50~1.59)* | 1.28(1.01~1.74)* |
50~59岁组 | 89 | 4.54(2.80~5.12) | 1.05(0.46~1.56) | 1.29(1.00~1.73)* |
60~69岁组 | 69 | 4.40(2.95~5.13)* | 1.02(0.53~1.55) | 1.26(1.02~1.64)* |
H值 | 20.511 | 24.103 | 0.304 | |
P值 | 0.000 | 0.000 | 0.987 | |
女性 | ||||
20~29岁组 | 102 | 4.02(2.89~5.06) | 0.75(0.41~1.47) | 1.45(1.03~2.16) |
30~39岁组 | 110 | 4.17(2.99~5.12) | 0.78(0.43~1.44) | 1.50(1.05~2.15) |
40~49岁组 | 91 | 4.35(3.09~5.09) | 0.89(0.43~1.65) | 1.43(1.02~2.13) |
50~59岁组 | 40 | 4.53(3.74~5.18) | 1.03(0.49~1.69) | 1.38(1.02~2.29) |
60~69岁组 | 29 | 4.68(2.83~5.16) | 1.30(0.65~1.64) | 1.54(1.02~2.17) |
H值 | 38.725 | 45.277 | 3.570 | |
P值 | 0.000 | 0.000 | 0.467 | |
年龄/岁 | LDL-C/(mmol/L) | apo A1/(g/L) | apo B/(g/L) | sd-LDL-C/(mmol/L) |
男性 | ||||
20~29岁组 | 1.99(1.03~2.73)* | 1.32(1.04~1.60)* | 0.70(0.40~1.00)* | 0.50(0.19~0.93)* |
30~39岁组 | 2.18(1.29~2.85)* | 1.34(1.04~1.65)* | 0.77(0.50~0.97)* | 0.58(0.29~0.98)* |
40~49岁组 | 2.22(1.25~2.79)* | 1.35(1.03~1.80)* | 0.79(0.47~0.97)* | 0.63(0.31~1.01)* |
50~59岁组 | 2.30(1.13~2.90) | 1.37(1.05~1.75)* | 0.85(0.44~1.02) | 0.63(0.26~0.99) |
60~69岁组 | 2.30(1.20~2.84) | 1.35(1.06~1.65)* | 0.83(0.49~1.04) | 0.59(0.30~1.03) |
H值 | 22.304 | 8.417 | 28.198 | 18.246 |
P值 | 0.000 | 0.077 | 0.000 | 0.001 |
女性 | ||||
20~29岁组 | 1.71(1.01~2.77) | 1.44(0.93~2.12) | 0.62(0.40~0.95) | 0.42(0.19~0.82) |
30~39岁组 | 1.90(1.10~2.72) | 1.55(1.06~2.00) | 0.67(0.41~0.99) | 0.46(0.23~1.03) |
40~49岁组 | 2.05(1.04~2.87) | 1.46(1.12~2.18) | 0.72(0.40~0.99) | 0.52(0.20~0.96) |
50~59岁组 | 2.39(1.19~3.23) | 1.51(1.09~2.20) | 0.81(0.40~1.09) | 0.62(0.26~1.15) |
60~69岁组 | 2.35(1.00~2.92) | 1.59(0.90~2.25) | 0.81(0.40~1.01) | 0.63(0.23~1.25) |
H值 | 56.504 | 10.403 | 55.499 | 45.491 |
P值 | 0.000 | 0.034 | 0.000 | 0.000 |
年龄/岁 | LDL-C/(mmol/L) | apo A1/(g/L) | apo B/(g/L) | sd-LDL-C/(mmol/L) |
男性 | ||||
20~29岁组 | 1.99(1.03~2.73)* | 1.32(1.04~1.60)* | 0.70(0.40~1.00)* | 0.50(0.19~0.93)* |
30~39岁组 | 2.18(1.29~2.85)* | 1.34(1.04~1.65)* | 0.77(0.50~0.97)* | 0.58(0.29~0.98)* |
40~49岁组 | 2.22(1.25~2.79)* | 1.35(1.03~1.80)* | 0.79(0.47~0.97)* | 0.63(0.31~1.01)* |
50~59岁组 | 2.30(1.13~2.90) | 1.37(1.05~1.75)* | 0.85(0.44~1.02) | 0.63(0.26~0.99) |
60~69岁组 | 2.30(1.20~2.84) | 1.35(1.06~1.65)* | 0.83(0.49~1.04) | 0.59(0.30~1.03) |
H值 | 22.304 | 8.417 | 28.198 | 18.246 |
P值 | 0.000 | 0.077 | 0.000 | 0.001 |
女性 | ||||
20~29岁组 | 1.71(1.01~2.77) | 1.44(0.93~2.12) | 0.62(0.40~0.95) | 0.42(0.19~0.82) |
30~39岁组 | 1.90(1.10~2.72) | 1.55(1.06~2.00) | 0.67(0.41~0.99) | 0.46(0.23~1.03) |
40~49岁组 | 2.05(1.04~2.87) | 1.46(1.12~2.18) | 0.72(0.40~0.99) | 0.52(0.20~0.96) |
50~59岁组 | 2.39(1.19~3.23) | 1.51(1.09~2.20) | 0.81(0.40~1.09) | 0.62(0.26~1.15) |
60~69岁组 | 2.35(1.00~2.92) | 1.59(0.90~2.25) | 0.81(0.40~1.01) | 0.63(0.23~1.25) |
H值 | 56.504 | 10.403 | 55.499 | 45.491 |
P值 | 0.000 | 0.034 | 0.000 | 0.000 |
组别 | 例数 | TC/(mmol/L) | TG/(mmol/L) | HDL-C/(mmol/L) |
---|---|---|---|---|
男性 | ||||
20~29岁组 | 94 | 4.15(2.80~4.90) | 0.85(0.43~1.41)* | 1.29(1.00~1.56)* |
30~39岁组 | 99 | 4.38(3.29~5.08)* | 1.05(0.61~1.53)* | 1.31(1.01~1.59)* |
40~49岁组 | 123 | 4.43(2.95~5.10) | 1.04(0.50~1.59)* | 1.28(1.01~1.74)* |
50~59岁组 | 89 | 4.54(2.80~5.12) | 1.05(0.46~1.56) | 1.29(1.00~1.73)* |
60~69岁组 | 69 | 4.40(2.95~5.13)* | 1.02(0.53~1.55) | 1.26(1.02~1.64)* |
H值 | 20.511 | 24.103 | 0.304 | |
P值 | 0.000 | 0.000 | 0.987 | |
女性 | ||||
20~29岁组 | 102 | 4.02(2.89~5.06) | 0.75(0.41~1.47) | 1.45(1.03~2.16) |
30~39岁组 | 110 | 4.17(2.99~5.12) | 0.78(0.43~1.44) | 1.50(1.05~2.15) |
40~49岁组 | 91 | 4.35(3.09~5.09) | 0.89(0.43~1.65) | 1.43(1.02~2.13) |
50~59岁组 | 40 | 4.53(3.74~5.18) | 1.03(0.49~1.69) | 1.38(1.02~2.29) |
60~69岁组 | 29 | 4.68(2.83~5.16) | 1.30(0.65~1.64) | 1.54(1.02~2.17) |
H值 | 38.725 | 45.277 | 3.570 | |
P值 | 0.000 | 0.000 | 0.467 | |
年龄/岁 | LDL-C/(mmol/L) | apo A1/(g/L) | apo B/(g/L) | sd-LDL-C/(mmol/L) |
男性 | ||||
20~29岁组 | 1.99(1.03~2.73)* | 1.32(1.04~1.60)* | 0.70(0.40~1.00)* | 0.50(0.19~0.93)* |
30~39岁组 | 2.18(1.29~2.85)* | 1.34(1.04~1.65)* | 0.77(0.50~0.97)* | 0.58(0.29~0.98)* |
40~49岁组 | 2.22(1.25~2.79)* | 1.35(1.03~1.80)* | 0.79(0.47~0.97)* | 0.63(0.31~1.01)* |
50~59岁组 | 2.30(1.13~2.90) | 1.37(1.05~1.75)* | 0.85(0.44~1.02) | 0.63(0.26~0.99) |
60~69岁组 | 2.30(1.20~2.84) | 1.35(1.06~1.65)* | 0.83(0.49~1.04) | 0.59(0.30~1.03) |
H值 | 22.304 | 8.417 | 28.198 | 18.246 |
P值 | 0.000 | 0.077 | 0.000 | 0.001 |
女性 | ||||
20~29岁组 | 1.71(1.01~2.77) | 1.44(0.93~2.12) | 0.62(0.40~0.95) | 0.42(0.19~0.82) |
30~39岁组 | 1.90(1.10~2.72) | 1.55(1.06~2.00) | 0.67(0.41~0.99) | 0.46(0.23~1.03) |
40~49岁组 | 2.05(1.04~2.87) | 1.46(1.12~2.18) | 0.72(0.40~0.99) | 0.52(0.20~0.96) |
50~59岁组 | 2.39(1.19~3.23) | 1.51(1.09~2.20) | 0.81(0.40~1.09) | 0.62(0.26~1.15) |
60~69岁组 | 2.35(1.00~2.92) | 1.59(0.90~2.25) | 0.81(0.40~1.01) | 0.63(0.23~1.25) |
H值 | 56.504 | 10.403 | 55.499 | 45.491 |
P值 | 0.000 | 0.034 | 0.000 | 0.000 |
年龄/岁 | LDL-C/(mmol/L) | apo A1/(g/L) | apo B/(g/L) | sd-LDL-C/(mmol/L) |
男性 | ||||
20~29岁组 | 1.99(1.03~2.73)* | 1.32(1.04~1.60)* | 0.70(0.40~1.00)* | 0.50(0.19~0.93)* |
30~39岁组 | 2.18(1.29~2.85)* | 1.34(1.04~1.65)* | 0.77(0.50~0.97)* | 0.58(0.29~0.98)* |
40~49岁组 | 2.22(1.25~2.79)* | 1.35(1.03~1.80)* | 0.79(0.47~0.97)* | 0.63(0.31~1.01)* |
50~59岁组 | 2.30(1.13~2.90) | 1.37(1.05~1.75)* | 0.85(0.44~1.02) | 0.63(0.26~0.99) |
60~69岁组 | 2.30(1.20~2.84) | 1.35(1.06~1.65)* | 0.83(0.49~1.04) | 0.59(0.30~1.03) |
H值 | 22.304 | 8.417 | 28.198 | 18.246 |
P值 | 0.000 | 0.077 | 0.000 | 0.001 |
女性 | ||||
20~29岁组 | 1.71(1.01~2.77) | 1.44(0.93~2.12) | 0.62(0.40~0.95) | 0.42(0.19~0.82) |
30~39岁组 | 1.90(1.10~2.72) | 1.55(1.06~2.00) | 0.67(0.41~0.99) | 0.46(0.23~1.03) |
40~49岁组 | 2.05(1.04~2.87) | 1.46(1.12~2.18) | 0.72(0.40~0.99) | 0.52(0.20~0.96) |
50~59岁组 | 2.39(1.19~3.23) | 1.51(1.09~2.20) | 0.81(0.40~1.09) | 0.62(0.26~1.15) |
60~69岁组 | 2.35(1.00~2.92) | 1.59(0.90~2.25) | 0.81(0.40~1.01) | 0.63(0.23~1.25) |
H值 | 56.504 | 10.403 | 55.499 | 45.491 |
P值 | 0.000 | 0.034 | 0.000 | 0.000 |
来源 | 建立方法 | 参考区间 | 样本例数 | 样本类型 | 检测方法 |
---|---|---|---|---|---|
本研究 | 百分位数法(P2.5~P97.5) | 男性 | 474 | 血浆 | 过氧化物酶法 |
20~29岁:0.19~0.93 mmol/L | 94 | ||||
30~39岁:0.29~0.98 mmol/L | 99 | ||||
40~49岁:0.31~1.01 mmol/L | 123 | ||||
50~59岁:0.26~0.99 mmol/L | 89 | ||||
60~69岁:0.30~1.03 mmol/L | 69 | ||||
女性 | 372 | ||||
20~29岁:0.19~0.8 mmol/L | 102 | ||||
30~39岁:0.23~1.03 mmol/L | 110 | ||||
40~49岁:0.20~0.96 mmol/L | 91 | ||||
50~59岁:0.26~1.15 mmol/L | 40 | ||||
60~69岁:0.23~1.25 mmol/L | 29 | ||||
本研究使用的试剂说明书 | 百分位数法(P2.5~P97.5) | 男性 | 2 199 | 血清 | 过氧化物酶法 |
20~44岁:0.246~1.393 mmol/L | |||||
45~79岁:0.264~1.362 mmol/L | |||||
女性 | |||||
20~54岁:0.234~1.109 mmol/L | |||||
55~79岁:0.264~1.362 mmol/L | |||||
来源 | 建立方法 | 参考区间 | 样本例数 | 样本类型 | 检测方法 |
本研究 | 百分位数法(P2.5~P97.5) | 男性 | 474 | 血浆 | 过氧化物酶法 |
20~29岁:0.19~0.93 mmol/L | 94 | ||||
30~39岁:0.29~0.98 mmol/L | 99 | ||||
40~49岁:0.31~1.01 mmol/L | 123 | ||||
50~59岁:0.26~0.99 mmol/L | 89 | ||||
60~69岁:0.30~1.03 mmol/L | 69 | ||||
女性 | 372 | ||||
20~29岁:0.19~0.8 mmol/L | 102 | ||||
30~39岁:0.23~1.03 mmol/L | 110 | ||||
40~49岁:0.20~0.96 mmol/L | 91 | ||||
50~59岁:0.26~1.15 mmol/L | 40 | ||||
60~69岁:0.23~1.25 mmol/L | 29 | ||||
本研究使用的试剂说明书 | 2 199 | 血清 | 过氧化物酶法 | ||
男性 | |||||
20~44岁:0.246~1.393 mmol/L | |||||
45~79岁:0.264~1.362 mmol/L | |||||
女性 | |||||
20~54岁:0.234~1.109 mmol/L | |||||
55~79岁:0.264~1.362 mmol/L | |||||
来源 | 建立方法 | 参考区间 | 样本例数 | 样本类型 | 检测方法 |
陈力平等[ | 95% 可信区间 | 男性 | 血清 | 过氧化物酶法 | |
≥18岁:0.59~0.64 mmol/L | 503 | ||||
18~29岁:0.50~0.59 mmol/L | 77 | ||||
30~69岁:0.63~0.69 mmol/L | 315 | ||||
≥70岁:0.50~0.58 mmol/L | 111 | ||||
女性 | |||||
≥18岁:0.50~0.60 mmol/L | 509 | ||||
18~29岁:0.43~0.52 mmol/L | 82 | ||||
30~69岁:0.59~0.64 mmol/L | 308 | ||||
≥70岁:0.50~0.58 mmol/L | 119 | ||||
丛辉等 [ | 中位数(P90) | 总人群:0.37(0.53) mmol/L | 254 | 血清 | 芯片电泳技术 |
男性:0.39(0.73) mmol/L | 137 | ||||
女性:0.36(0.52) mmol/L | 117 | ||||
20~29岁:0.27(0.48) mmol/L | 65 | ||||
30~39岁:0.28(0.43) mmol/L | 65 | ||||
40~49岁:0.41(0.79) mmol/L | 46 | ||||
50~69岁:0.45(0.85) mmol/L | 35 | ||||
70~89岁:0.32(0.57) mmol/L | 43 | ||||
HIRANO等[ | $\overline{x}$±s | 20~72岁:0.47~1.14 mmol/L [(31±13)mg/dL] | 313 | 血浆 | 沉淀法 |
ITO等[ | 95%参考区间 | 0.24~0.88 mmol/L | 460 | 血浆 | 均相法 |
来源 | 建立方法 | 参考区间 | 样本例数 | 样本类型 | 检测方法 |
---|---|---|---|---|---|
本研究 | 百分位数法(P2.5~P97.5) | 男性 | 474 | 血浆 | 过氧化物酶法 |
20~29岁:0.19~0.93 mmol/L | 94 | ||||
30~39岁:0.29~0.98 mmol/L | 99 | ||||
40~49岁:0.31~1.01 mmol/L | 123 | ||||
50~59岁:0.26~0.99 mmol/L | 89 | ||||
60~69岁:0.30~1.03 mmol/L | 69 | ||||
女性 | 372 | ||||
20~29岁:0.19~0.8 mmol/L | 102 | ||||
30~39岁:0.23~1.03 mmol/L | 110 | ||||
40~49岁:0.20~0.96 mmol/L | 91 | ||||
50~59岁:0.26~1.15 mmol/L | 40 | ||||
60~69岁:0.23~1.25 mmol/L | 29 | ||||
本研究使用的试剂说明书 | 百分位数法(P2.5~P97.5) | 男性 | 2 199 | 血清 | 过氧化物酶法 |
20~44岁:0.246~1.393 mmol/L | |||||
45~79岁:0.264~1.362 mmol/L | |||||
女性 | |||||
20~54岁:0.234~1.109 mmol/L | |||||
55~79岁:0.264~1.362 mmol/L | |||||
来源 | 建立方法 | 参考区间 | 样本例数 | 样本类型 | 检测方法 |
本研究 | 百分位数法(P2.5~P97.5) | 男性 | 474 | 血浆 | 过氧化物酶法 |
20~29岁:0.19~0.93 mmol/L | 94 | ||||
30~39岁:0.29~0.98 mmol/L | 99 | ||||
40~49岁:0.31~1.01 mmol/L | 123 | ||||
50~59岁:0.26~0.99 mmol/L | 89 | ||||
60~69岁:0.30~1.03 mmol/L | 69 | ||||
女性 | 372 | ||||
20~29岁:0.19~0.8 mmol/L | 102 | ||||
30~39岁:0.23~1.03 mmol/L | 110 | ||||
40~49岁:0.20~0.96 mmol/L | 91 | ||||
50~59岁:0.26~1.15 mmol/L | 40 | ||||
60~69岁:0.23~1.25 mmol/L | 29 | ||||
本研究使用的试剂说明书 | 2 199 | 血清 | 过氧化物酶法 | ||
男性 | |||||
20~44岁:0.246~1.393 mmol/L | |||||
45~79岁:0.264~1.362 mmol/L | |||||
女性 | |||||
20~54岁:0.234~1.109 mmol/L | |||||
55~79岁:0.264~1.362 mmol/L | |||||
来源 | 建立方法 | 参考区间 | 样本例数 | 样本类型 | 检测方法 |
陈力平等[ | 95% 可信区间 | 男性 | 血清 | 过氧化物酶法 | |
≥18岁:0.59~0.64 mmol/L | 503 | ||||
18~29岁:0.50~0.59 mmol/L | 77 | ||||
30~69岁:0.63~0.69 mmol/L | 315 | ||||
≥70岁:0.50~0.58 mmol/L | 111 | ||||
女性 | |||||
≥18岁:0.50~0.60 mmol/L | 509 | ||||
18~29岁:0.43~0.52 mmol/L | 82 | ||||
30~69岁:0.59~0.64 mmol/L | 308 | ||||
≥70岁:0.50~0.58 mmol/L | 119 | ||||
丛辉等 [ | 中位数(P90) | 总人群:0.37(0.53) mmol/L | 254 | 血清 | 芯片电泳技术 |
男性:0.39(0.73) mmol/L | 137 | ||||
女性:0.36(0.52) mmol/L | 117 | ||||
20~29岁:0.27(0.48) mmol/L | 65 | ||||
30~39岁:0.28(0.43) mmol/L | 65 | ||||
40~49岁:0.41(0.79) mmol/L | 46 | ||||
50~69岁:0.45(0.85) mmol/L | 35 | ||||
70~89岁:0.32(0.57) mmol/L | 43 | ||||
HIRANO等[ | $\overline{x}$±s | 20~72岁:0.47~1.14 mmol/L [(31±13)mg/dL] | 313 | 血浆 | 沉淀法 |
ITO等[ | 95%参考区间 | 0.24~0.88 mmol/L | 460 | 血浆 | 均相法 |
[1] |
JAAKKOLA O, SOLAKIVI T, TERTOV V V, et al. Characteristics of low-density lipoprotein subfractions from patients with coronary artery disease[J]. Coron Artery Dis, 1993,4(4):379-385.
DOI URL |
[2] |
BERNEIS K K, KRAUSS R M. Metabolic origins and clinical significance of LDL heterogeneity[J]. J Lipid Res, 2002,43(9):1363-1379.
DOI URL |
[3] | VANAVANAN S, SRISAWASDI P, ROCHANAWUTANON M, et al. Comparison of a direct enzymatic assay and polyacrylamide tube gel electrophoresis for measurement of small,dense low-density lipoprotein cholesterol[J]. Clin Chem Lab Med, 2015,53(1):139-148. |
[4] | 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016,31(10):937-953. |
[5] | Clinical and Laboratory Standards Institute. Defining,establishing,and verifying reference intervals in the clinical laboratory[S]. C28-A3,CLSI, 2008. |
[6] | 陈力平, 林杰, 孔维菊, 等. 不同血脂水平人群小而密LDL胆固醇分布及其与血脂组分的相关性[J]. 中华检验医学杂志, 2012,35(4):354-358. |
[7] | 丛辉, 王惠民, 鞠少卿, 等. 南通地区健康体检人群小而密低密度脂蛋白水平调查[J]. 中华检验医学杂志, 2009,32(12):1389-1393. |
[8] |
HIRANO T, ITO Y, KOBA S, et al. Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method[J]. Arterioscler Thromb Vasc Biol, 2004,24(3):558-563.
DOI URL |
[9] |
ITO Y, FUJIMURA M, OHTA M, et al. Development of a homogeneous assay for measurement of small dense LDL cholesterol[J]. Clin Chem, 2011,57(1):57-65.
DOI URL |
[10] | 吴嘉, 汪俊军. 小而密低密度脂蛋白检测方法及应用进展[J]. 中华检验医学杂志, 2017,40(6):417-420. |
[11] | IVANOVA E A, MYASOEDOVA V A, MELNICHENKO A A, et al. Small dense low-density lipoprotein as biomarker for atherosclerotic diseases[J]. Oxid Med Cell Longev, 2017,2017:1273042. |
[12] |
National Cholesterol Education Program(NCEP) Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel Ⅲ). Third report of the National Cholesterol Education Program(NCEP) expert panel on detection,evaluation,and treatment of high blood cholesterol in adults(adult treatment panel Ⅲ) final report[J]. Circulation, 2002,106(25):3143-3421.
DOI URL |
[13] | 刘芳, 刘义庆, 成士清, 等. 济南地区不同性别、年龄人群血清小而密低密度脂蛋白胆固醇水平调查[J]. 广西医学, 2018,40(17):2018-2019. |
[14] |
CERIOTTI F. Quality specifications for the extra-analytical phase of laboratory testing:reference intervals and decision limits[J]. Clin Biochem, 2017,50(10-11):595-598.
DOI URL |
[15] | 李淑丽, 陆善词, 王军, 等. 表观健康成人血清谷胱甘肽还原酶参考区间的建立[J]. 检验医学, 2019,34(10):908-912. |
[16] |
SAKAI K, KOBA S, NAKAMURA Y, et al. Small dense low-density lipoprotein cholesterol is a promising biomarker for secondary prevention in older men with stable coronary artery disease[J]. Geriatr Gerontol Int, 2018,18(6):965-972.
DOI URL |
[1] | FU Yi, YANG Xuesong, JIN Ligang, ZHAI Hongli, JIN Xiaoling. Correlation between small and dense low-density lipoprotein cholesterol and acute coronary syndrome with the occurrence of long-term adverse cardiovascular events [J]. Laboratory Medicine, 2023, 38(9): 878-883. |
[2] | MA Jianguo, LI Hongchun. Correlation between blood lipid levels and cardiac function indexes in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(7): 659-664. |
[3] | JIN Suli, ZHAO Jing, ZHANG Jie, HOU Xuening, FANG Yanchao, YANG Li, MI Yujing. Relationship between thyroid hormones and bile acid subfractions and blood lipids in Graves' disease patients [J]. Laboratory Medicine, 2023, 38(6): 563-568. |
[4] | WU Youhong, SONG Yunxiao, ZHU Yong, GE Wen, BIAN Xiaobo, YUAN Wenhua, ZHAO Zhiyun. Role of blood lipid levels in assessment of coronary artery stenosis and its treatment in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(6): 584-589. |
[5] | AN Yinghong, YAO Kechun, SU Chengming, TANG Jinhua, YANG Lixin, GAO Jie, XU Yanting, YAN Qiuhong, ZHAN Hongyan, MA Yueyun. Survey of serum homocysteine levels of apparently healthy subjects in Beijing [J]. Laboratory Medicine, 2023, 38(11): 1036-1040. |
[6] | ZHAO Yanhong, FU Lin, LIU Biao, XIAO Meifang. Reference interval of lactate dehydrogenase among 3-14-year-old population in Hainan [J]. Laboratory Medicine, 2023, 38(11): 1041-1043. |
[7] | XING Baobao, CAO Yinfang. Predictive value of sd-LDL-C/LDL-C ratio for in-stent restenosis in patients with AMI after interventional therapy [J]. Laboratory Medicine, 2023, 38(10): 941-945. |
[8] | XU Qianqian, JIANG Wangqing, SHEN Linjie, LU Yingjie, CHEN Jian, JIANG Haoqin. Establishment of the reference intervals for related parameters of adult reticulocytes in Shanghai [J]. Laboratory Medicine, 2022, 37(7): 641-645. |
[9] | SHEN Jianguo, LI Tingting, SONG Yunxiao, BIAN Xiaobo, ZHANG Linlin, JIN Xiaoling. Clinical role of blood lipid in brittle fracture elderly patients with osteoporosis [J]. Laboratory Medicine, 2022, 37(6): 535-538. |
[10] | MIAO Linzi, LU Yao, QU Chenxue, YOU Ran, GONG Yan. Establishment of the reference intervals of leukocyte surface CD64 and HLA-DR indexes for healthy adults and related factors [J]. Laboratory Medicine, 2022, 37(3): 240-245. |
[11] | LU Youli, YANG Shuangshuang, ZHANG Meiwei, OU Meixian, DONG Chunxia, SHEN Weiwei, JIANG Fengli, LI Shuijun. Simultaneous determination of 5 steroid hormones in human serum by ultra-performance liquid chromatography-tandem mass spectrometry and establishment of reference intervals in healthy adults [J]. Laboratory Medicine, 2022, 37(2): 165-173. |
[12] | YU Jianhong, PENG Qingyuan, YIN Minggang. Establishment of reference intervals of serum PGⅠ,PGⅡ and PGR for apparently healthy subjects in Zigong [J]. Laboratory Medicine, 2022, 37(1): 23-27. |
[13] | PENG Yanjun, HAN Xuejing, TANG Hongxia, CHEN Junmeng, JIA Kegang. Correlation between nuclear magnetic resonance spectroscopy and traditional biochemical determination methods analyzer for determining blood lipid [J]. Laboratory Medicine, 2021, 36(7): 733-737. |
[14] | DAI Yanpeng, YUAN Enwu, LIU Junjie, LI Yushan, WANG Quanxian. Analysis of the appropriate levels of blood lipid among healthy pregnant women in Zhengzhou [J]. Laboratory Medicine, 2021, 36(6): 604-608. |
[15] | WANG Linlin, FAN Jun, YE Chenyu, YING Chunmei. Correlation between blood lipid and carotid atherosclerotic plaque in elderly patients with coronary heart disease [J]. Laboratory Medicine, 2021, 36(6): 618-622. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||